Option Care Health, Inc. $OPCH Stock Position Reduced by HighTower Advisors LLC

Key Points

• HighTower Advisors LLC reduced its stake in Option Care Health by 16.9%, selling 79,140 shares and ending up with approximately 388,942 shares valued at $13.6 million.
• Institutional investors hold 98.05% of Option Care Health's stock, with several firms increasing their positions, including Bessemer Group, which raised its holdings by 62.3% in the first quarter.
• Analysts have upgraded the stock's rating to "buy" with price targets rising to as much as $40.00, signaling positive sentiment towards Option Care Health's future performance.

HighTower Advisors LLC reduced its position in shares of Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 16.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 388,942 shares of the company's stock after selling 79,140 shares during the period. HighTower Advisors LLC owned approximately 0.24% of Option Care Health worth $13,594,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in OPCH. Nuveen LLC purchased a new position in Option Care Health in the first quarter valued at about $70,965,000. Allspring Global Investments Holdings LLC increased its holdings in Option Care Health by 6,525,926.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 1,500,986 shares of the company's stock valued at $52,459,000 after buying an additional 1,500,963 shares in the last quarter. Voloridge Investment Management LLC acquired a new stake in shares of Option Care Health in the fourth quarter valued at approximately $27,428,000. Freestone Grove Partners LP acquired a new stake in shares of Option Care Health in the fourth quarter valued at approximately $17,487,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Option Care Health by 17.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,988,051 shares of the company's stock valued at $92,518,000 after purchasing an additional 591,042 shares during the last quarter. 98.05% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Option Care Health

In related news, Director Harry M. Jansen Kraemer, Jr. purchased 36,000 shares of Option Care Health stock in a transaction dated Wednesday, August 20th. The stock was bought at an average cost of $27.15 per share, with a total value of $977,400.00. Following the purchase, the director owned 375,390 shares in the company, valued at approximately $10,191,838.50. The trade was a 10.61% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Timothy P. Sullivan bought 20,000 shares of the company's stock in a transaction that occurred on Thursday, August 21st. The stock was acquired at an average price of $27.51 per share, for a total transaction of $550,200.00. Following the completion of the acquisition, the director directly owned 49,229 shares in the company, valued at approximately $1,354,289.79. This represents a 68.43% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 0.64% of the company's stock.

Option Care Health Stock Up 5.1%

OPCH stock traded up $1.4220 during mid-day trading on Friday, hitting $29.2620. 761,756 shares of the company were exchanged, compared to its average volume of 1,851,062. The company has a market capitalization of $4.75 billion, a PE ratio of 23.35, a price-to-earnings-growth ratio of 1.72 and a beta of 0.79. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.81. Option Care Health, Inc. has a twelve month low of $21.39 and a twelve month high of $35.53. The firm has a fifty day simple moving average of $29.98 and a 200 day simple moving average of $31.77.

Option Care Health (NASDAQ:OPCH - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.01. Option Care Health had a net margin of 3.93% and a return on equity of 17.53%. The company had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.35 billion. During the same period last year, the business earned $0.30 EPS. The firm's revenue for the quarter was up 15.4% compared to the same quarter last year. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. On average, research analysts forecast that Option Care Health, Inc. will post 1.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on OPCH shares. Barrington Research restated an "outperform" rating and set a $38.00 target price on shares of Option Care Health in a research report on Thursday, July 10th. Citigroup restated an "outperform" rating on shares of Option Care Health in a research report on Thursday, July 31st. JMP Securities raised their target price on shares of Option Care Health from $36.00 to $38.00 and gave the stock a "market outperform" rating in a research report on Thursday, July 31st. Finally, UBS Group raised shares of Option Care Health from a "neutral" rating to a "buy" rating and increased their price target for the stock from $38.00 to $40.00 in a research note on Wednesday, April 30th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $35.75.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.